Simplex Trading
RLMD icon

Simplex Trading’s Relmada Therapeutics RLMD Stock Holding History

Simplex Trading’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$421K Buy
60,500
+28,600
+90% +$135K ﹤0.01% 3477
2025
Q4 		$154K Buy
+31,900
New +$107K ﹤0.01% 4506
2025
Q1 		– Sell
-91,400
Closed -$47K – 9475
2024
Q4 		$47K Buy
91,400
+55,300
+153% +$135K ﹤0.01% 5940
2024
Q3 		$116K Buy
36,100
+29,700
+464% +$96.2K ﹤0.01% 5077
2024
Q2 		$19K Sell
6,400
-100
-2% -$362 ﹤0.01% 6948
2024
Q1 		$30K Buy
6,500
+5,100
+364% +$24.6K ﹤0.01% 6760
2023
Q4 		$5K Sell
1,400
-6,500
-82% -$19.2K ﹤0.01% 7894
2023
Q3 		$23K Buy
7,900
+6,500
+464% +$19.3K ﹤0.01% 6510
2023
Q2 		$3K Sell
1,400
-4,900
-78% -$13.5K ﹤0.01% 8273
2023
Q1 		$14K Sell
6,300
-155,300
-96% -$536K ﹤0.01% 7263
2022
Q4 		$563K Buy
161,600
+42,600
+36% +$374K ﹤0.01% 3043
2022
Q3 		$4.41M Sell
119,000
-34,000
-22% -$942K 0.01% 1288
2022
Q2 		$2.9M Buy
153,000
+82,300
+116% +$1.8M ﹤0.01% 1532
2022
Q1 		$1.91M Buy
70,700
+69,700
+6,970% +$1.44M ﹤0.01% 2162
2021
Q4 		$22K Sell
1,000
-9,400
-90% -$209K ﹤0.01% 8266
2021
Q3 		$349K Hold
10,400
– – ﹤0.01% 4674
2021
Q2 		$332K Buy
10,400
+10,344
+18,471% +$359K ﹤0.01% 4802
2021
Q1 		$197K Buy
56
+13
+30% +$455 ﹤0.01% 4764
2020
Q4 		$137K Sell
43
-64
-60% -$2.2K ﹤0.01% 5099
2020
Q3 		$402K Buy
107
+68
+174% +$2.63K ﹤0.01% 3260
2020
Q2 		$174K Buy
39
+33
+550% +$1.4K ﹤0.01% 4148
2020
Q1 		$20K Sell
6
-7
-54% -$282 ﹤0.01% 5962
2019
Q4 		$50K Buy
+13
New +$395 ﹤0.01% 5183

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Simplex Trading's RLMD Position: Q1 2026 in Review

Simplex Trading sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 18,611 shares — an estimated $88.1K sold.

Simplex Trading first reported a position in RLMD in Q4 2019 and held it in 18 quarters. The position peaked at $290K in Q1 2021. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Simplex Trading reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 18,611 Relmada Therapeutics shares in Q1 2026, an estimated $88.1K.
  • Simplex Trading first reported a position in Relmada Therapeutics in Q4 2019 and held it in 18 quarters.
  • Simplex Trading's Relmada Therapeutics position peaked at $290K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.